NEW YORK (
) hit a new 52-week high Friday as it is currently trading at $74.14, above its previous 52-week high of $73.20 with 2.6 million shares traded as of 9:50 a.m. ET. Average volume has been 8.2 million shares over the past 30 days.
Gilead has a market cap of $108.99 billion and is part of the health care sector and drugs industry. Shares are up 93.5% year to date as of the close of trading on Thursday.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. The company has a P/E ratio of 39.1, above the S&P 500 P/E ratio of 17.7.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full
52-week high stocks
or get investment ideas from our